KR102567295B1 - 항-N3pGlu 아밀로이드 베타 펩티드 항체 및 그의 용도 - Google Patents

항-N3pGlu 아밀로이드 베타 펩티드 항체 및 그의 용도 Download PDF

Info

Publication number
KR102567295B1
KR102567295B1 KR1020227001314A KR20227001314A KR102567295B1 KR 102567295 B1 KR102567295 B1 KR 102567295B1 KR 1020227001314 A KR1020227001314 A KR 1020227001314A KR 20227001314 A KR20227001314 A KR 20227001314A KR 102567295 B1 KR102567295 B1 KR 102567295B1
Authority
KR
South Korea
Prior art keywords
ser
antibody
val
gly
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227001314A
Other languages
English (en)
Korean (ko)
Other versions
KR20220011800A (ko
Inventor
로널드 브래들리 데마토스
지롱 루
잉 탕
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20220011800A publication Critical patent/KR20220011800A/ko
Application granted granted Critical
Publication of KR102567295B1 publication Critical patent/KR102567295B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
    • C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0684—Cells of the urinary tract or kidneys
    • C12N5/0686—Kidney cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
KR1020227001314A 2017-04-20 2018-04-16 항-N3pGlu 아밀로이드 베타 펩티드 항체 및 그의 용도 Active KR102567295B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762487550P 2017-04-20 2017-04-20
US62/487,550 2017-04-20
PCT/US2018/027718 WO2018194951A1 (en) 2017-04-20 2018-04-16 ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF
KR1020197030416A KR102352670B1 (ko) 2017-04-20 2018-04-16 항-N3pGlu 아밀로이드 베타 펩티드 항체 및 그의 용도

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020197030416A Division KR102352670B1 (ko) 2017-04-20 2018-04-16 항-N3pGlu 아밀로이드 베타 펩티드 항체 및 그의 용도

Publications (2)

Publication Number Publication Date
KR20220011800A KR20220011800A (ko) 2022-01-28
KR102567295B1 true KR102567295B1 (ko) 2023-08-16

Family

ID=62111232

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227001314A Active KR102567295B1 (ko) 2017-04-20 2018-04-16 항-N3pGlu 아밀로이드 베타 펩티드 항체 및 그의 용도
KR1020197030416A Active KR102352670B1 (ko) 2017-04-20 2018-04-16 항-N3pGlu 아밀로이드 베타 펩티드 항체 및 그의 용도

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020197030416A Active KR102352670B1 (ko) 2017-04-20 2018-04-16 항-N3pGlu 아밀로이드 베타 펩티드 항체 및 그의 용도

Country Status (28)

Country Link
US (3) US10647759B2 (https=)
EP (1) EP3612559A1 (https=)
JP (3) JP6900500B2 (https=)
KR (2) KR102567295B1 (https=)
CN (2) CN117024583A (https=)
AR (1) AR111208A1 (https=)
AU (2) AU2018255221B2 (https=)
BR (1) BR112019018810A2 (https=)
CA (1) CA3058482C (https=)
CL (1) CL2019002922A1 (https=)
CO (1) CO2019011349A2 (https=)
CR (1) CR20190445A (https=)
DO (1) DOP2019000241A (https=)
EA (1) EA201992163A1 (https=)
EC (1) ECSP19075146A (https=)
IL (1) IL269003B2 (https=)
JO (1) JOP20190247A1 (https=)
MA (1) MA50144A (https=)
MX (2) MX2019012445A (https=)
NZ (1) NZ758066A (https=)
PE (1) PE20200011A1 (https=)
PH (1) PH12019502361A1 (https=)
SA (1) SA519410311B1 (https=)
SG (1) SG11201909022PA (https=)
TW (2) TWI789644B (https=)
UA (1) UA126806C2 (https=)
WO (1) WO2018194951A1 (https=)
ZA (2) ZA201906159B (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
TWI789644B (zh) * 2017-04-20 2023-01-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
JOP20210265A1 (ar) 2019-03-26 2023-01-30 Janssen Pharmaceutica Nv الأجسام المضادة لبيروغلوتامات أميلويد بيتا واستخداماتها
WO2021151011A2 (en) * 2020-01-24 2021-07-29 The Board Of Trustees Of Western Michigan University Treatment of neurodegenerative proteinopathies using fas apoptosis inhibitory molecule (faim) or a fragment and/or a mimetic thereof
KR20230078748A (ko) * 2020-10-02 2023-06-02 일라이 릴리 앤드 캄파니 항체 정제 공정에서의 숙주 세포 단백질 함량을 감소시키는 방법 및 감소된 숙주 세포 단백질 함량을 가지는 항체 조성물
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗類澱粉β抗體及其用途
TW202300518A (zh) 2021-03-12 2023-01-01 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
JP7306746B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
JP7306745B2 (ja) * 2021-09-16 2023-07-11 株式会社ユニバーサルエンターテインメント 遊技機
JP7268910B2 (ja) * 2021-09-16 2023-05-08 株式会社ユニバーサルエンターテインメント 遊技機
AU2022371475A1 (en) * 2021-10-22 2024-05-09 Eli Lilly And Company O-glcnacase (oga) inhibitor combination therapy
MX2024005146A (es) 2021-10-29 2024-05-13 Lilly Co Eli Compuestos y metodos dirigidos a interleucina-34.
CN118475610A (zh) 2021-10-29 2024-08-09 伊莱利利公司 靶向白细胞介素-34的化合物和方法
KR20240105403A (ko) 2021-10-29 2024-07-05 일라이 릴리 앤드 캄파니 인터류킨-34를 표적화하는 화합물 및 방법
EP4422751A1 (en) 2021-10-29 2024-09-04 Eli Lilly and Company Compounds and methods targeting interleukin-34
CA3243602A1 (en) 2022-02-03 2023-08-10 Eli Lilly And Company Regional Tau Imaging for the Diagnosis and Treatment of Alzheimer's Disease
CN117327168A (zh) * 2022-06-24 2024-01-02 厦门大学 B2M-GluN1封闭肽、其药物组合物及用途
KR20250107906A (ko) * 2022-11-17 2025-07-14 일라이 릴리 앤드 캄파니 항-N3pGlu 아밀로이드 베타 항체, 그의 용량 및 용도
PE20252307A1 (es) 2022-12-22 2025-09-22 Bioarctic Ab Anticuerpo que se une a abetape3
WO2025106313A1 (en) 2023-11-14 2025-05-22 Eli Lilly And Company Fc RECEPTOR BASED ASSAYS FOR ANALYZING IgG ANTIBODIES
WO2025228316A1 (en) * 2024-04-28 2025-11-06 Jacobio Pharmaceuticals Co., Ltd. Anti-n3pglu amyloid beta antibodies and uses thereof
WO2025255300A1 (en) * 2024-06-06 2025-12-11 Eli Lilly And Company FORMULATIONS FOR ANTI-N3pGlu AMYLOID BETA ANTIBODIES
WO2025262228A1 (en) 2024-06-20 2025-12-26 Bioarctic Ab Bispecific binding molecule
WO2026012421A1 (zh) * 2024-07-11 2026-01-15 齐鲁制药有限公司 抗N3pGlu淀粉样蛋白β抗体及其用途
CN118459583B (zh) * 2024-07-11 2024-09-10 齐鲁制药有限公司 抗N3pGlu淀粉样蛋白β抗体及其用途
WO2026075947A1 (en) 2024-10-01 2026-04-09 Eli Lilly And Company Dosing regimens for early alzheimer's disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012021475A2 (en) 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1257584T1 (de) * 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
US7122374B1 (en) 2002-04-09 2006-10-17 Takaomi Saido Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
WO2004013172A2 (en) 2002-07-24 2004-02-12 Innogenetics N.V. Fragments of beta-amyloid as targets for vaccination against alzheimer disease
EP1666061A1 (en) 2003-09-09 2006-06-07 Takeda Pharmaceutical Company Limited Use of antibody
MX2007000998A (es) 2004-07-30 2007-07-11 Rinat Neuroscience Corp Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos.
UY29504A1 (es) * 2005-04-29 2006-10-31 Rinat Neuroscience Corp Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos.
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
CN102123726A (zh) 2008-06-12 2011-07-13 阿费里斯股份公司 用于治疗与帕金森氏病有关的症状的化合物
EP2321348A2 (en) 2008-07-09 2011-05-18 University of Zürich Method of promoting neurogenesis
WO2010009987A2 (en) 2008-07-21 2010-01-28 Probiodrug Ag Diagnostic antibody assay
WO2011151076A2 (en) 2010-06-04 2011-12-08 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin MONOCLONAL ANTIBODIES TARGETING Αβ OLIGOMERS
PL3042917T3 (pl) * 2010-08-12 2018-07-31 Eli Lilly And Company Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
WO2015175769A1 (en) 2014-05-15 2015-11-19 Biogen Ma Inc. Methods for the detection of amyloid beta oligomers in biological samples
TWI599358B (zh) * 2014-09-16 2017-09-21 美國禮來大藥廠 組合療法
TWI703159B (zh) * 2015-04-13 2020-09-01 美商輝瑞股份有限公司 Bcma特異性治療性抗體及其用途
JOP20170004B1 (ar) 2016-01-15 2022-09-15 Lilly Co Eli الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
TWI798751B (zh) * 2016-07-01 2023-04-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途
TWI789644B (zh) * 2017-04-20 2023-01-11 美商美國禮來大藥廠 抗－N3pGlu類澱粉β肽抗體及其用途

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012021475A2 (en) 2010-08-12 2012-02-16 Eli Lilly And Company ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF

Also Published As

Publication number Publication date
IL269003A (en) 2019-10-31
ECSP19075146A (es) 2019-10-31
JOP20190247A1 (ar) 2019-10-20
US20210371509A1 (en) 2021-12-02
CL2019002922A1 (es) 2020-03-13
JP6900500B2 (ja) 2021-07-07
DOP2019000241A (es) 2019-10-15
US10647759B2 (en) 2020-05-12
CA3058482C (en) 2023-05-09
SG11201909022PA (en) 2019-11-28
IL269003B1 (en) 2025-06-01
US20200262902A1 (en) 2020-08-20
AR111208A1 (es) 2019-06-12
TW201902924A (zh) 2019-01-16
KR20190129100A (ko) 2019-11-19
CA3058482A1 (en) 2018-10-25
WO2018194951A1 (en) 2018-10-25
MX2019012445A (es) 2020-01-13
JP2020510081A (ja) 2020-04-02
CN117024583A (zh) 2023-11-10
BR112019018810A2 (pt) 2020-05-05
KR20220011800A (ko) 2022-01-28
PH12019502361A1 (en) 2020-07-13
SA519410311B1 (ar) 2022-03-20
CO2019011349A2 (es) 2019-10-31
US20180305444A1 (en) 2018-10-25
ZA201906159B (en) 2026-03-25
KR102352670B1 (ko) 2022-01-19
AU2018255221A1 (en) 2019-09-19
JP2023058623A (ja) 2023-04-25
PE20200011A1 (es) 2020-01-06
TW202120541A (zh) 2021-06-01
CR20190445A (es) 2019-11-06
US11078261B2 (en) 2021-08-03
EA201992163A1 (ru) 2020-03-02
CN110582511B (zh) 2023-08-08
TWI789644B (zh) 2023-01-11
EP3612559A1 (en) 2020-02-26
JP2021151253A (ja) 2021-09-30
MA50144A (fr) 2020-07-29
UA126806C2 (uk) 2023-02-08
AU2021203927A1 (en) 2021-07-08
IL269003B2 (en) 2025-10-01
JP7227312B2 (ja) 2023-02-21
JP7532571B2 (ja) 2024-08-13
TWI705975B (zh) 2020-10-01
ZA202007868B (en) 2023-06-28
AU2021203927B2 (en) 2024-03-21
CN110582511A (zh) 2019-12-17
AU2018255221B2 (en) 2021-07-01
MX2022011817A (es) 2022-10-10
NZ758066A (en) 2022-10-28

Similar Documents

Publication Publication Date Title
AU2021203927B2 (en) Anti-N3pGlu Amyloid Beta Peptide Antibodies And Uses Thereof
CN103781802B (zh) 针对pcsk9的抗体及其用途
KR102344620B1 (ko) 항-cd137 항체
CN111051343B (zh) Il-6r抗体、其抗原结合片段及医药用途
CN113015557B (zh) 抗alpha-突触核蛋白抗体及其用途
KR20230078748A (ko) 항체 정제 공정에서의 숙주 세포 단백질 함량을 감소시키는 방법 및 감소된 숙주 세포 단백질 함량을 가지는 항체 조성물
KR20250038810A (ko) 항-pd-1 항체와의 조합을 위한 항-cd137 항체
KR102432046B1 (ko) 항-pd-l1 항체와의 조합을 위한 항-cd137 항체
RU2812765C2 (ru) Антитела к альфа-синуклеину и варианты их применения
HK40054347A (en) Anti-alpha-synuclein antibodies and uses thereof
HK40054347B (zh) 抗alpha-突触核蛋白抗体及其用途

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220113

Application number text: 1020197030416

Filing date: 20191016

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220427

Patent event code: PE09021S01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20221130

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230630

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230810

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230811

End annual number: 3

Start annual number: 1

PG1601 Publication of registration